Skip to main content

Rapid COVID-19 Passive Therapy Response Platform

Deliverables

Proven pre-clinical safety and efficacy of the SARS-CoV-2 vaccine and antibody drug product

Preclinical studies demonstrating the safety and efficacy of passive therapy in rodent models Data will be shared with the EIC

Highly purified antibody therapy for preclinical studies

Characterised lead candidates will be expressed and antibody purified for the direct passive therapy in preclinical studies Sufficient purified antibodyprotein will be generated to ensure full preclinical studies can be performed

Antibody DNA sequence of lead candidate(s)

Recombinant antibody DNA and sequence information of lead candidates that can be provided to partners for cloningmanufacture in partner expression systems Providing recombinant DNA can provide rapid scaling through multiple partners

Deployment of SARS-Cov-2 antibody passive vaccine therapy

Remedy Biologics will partner with appropriate bigpharma and EU Government authorities to produce and deploy vaccines

Searching for OpenAIRE data...